[Aug 1, 2025]AriBio Showcases AR1001 Alzheimer’s Research at AAIC 2025

Phase 3 top-line results expected in 2026, Laying the groundwork for exclusive licensing deals with big pharma and commercialization preparations AriBio announced on July 31st that four research abstracts related to its investigational Alzheimer’s treatment were presented at the Alzheimer’s Association International Conference (AAIC 2025), held in Toronto, Canada, beginning on July 27. The research abstracts presented by AriBio at AAIC 2025 included: △ Evaluating AR1001 as Monotherapy from a Phase 2 Study in Mild to Moderate Alzheimer’s Disease Patients. △ Preliminary Survey Insights on Neurologists’ Views of a Potential Oral, Safe Disease-Modifying Therapy for Early Alzheimer’s Disease. △ Multiple Beneficial Effects of AR1001 on Aβ-Induced Changes in Human Minibrain. △ Interlaboratory Comparison of Amyloid-Beta [Aβ1-42], [Aβ1-40] and its Ratio Derived from CSF at Two Reference Laboratories using the Lumipulse® platform. Samples collected from Participants in the Phase 3 clinical trial in partnership with Fujirebio. In the clinical subgroup analysis, participants receiving AR1001 30 mg without concomitant Alzheimer’s medications demonstrated statistically significant improvement on the ADAS-Cog 13 after 26 weeks, alongside reductions in plasma pTau-181 and pTau-217. These findings support further investigation into AR1001 as a potential monotherapy for the treatment of Alzheimer’s disease. A separate clinician survey, involving neurologists from the U.S. and Europe, found strong interest in a once daily, oral small-molecule, disease-modifying therapies (DMTs) with multimodal mechanisms, a favorable safety profile, and efficacy. These findings can help guide payer value models, physician utilization models, and strategies for the adoption of safer, lower-burden therapies. The minibrain model study demonstrated AR1001’s capacity to reduce oAβ and inflammation in both astrocytes and microglia, while providing neuroprotective effects in neurons. Reductions in pTau-181 and pTau-217 levels were also observed, highlighting AR1001’s multiple beneficial effects across key brain cell types. Finally, an interlaboratory comparison of the Fujirebio Lumipulse® CSF assay platform demonstrated statistically identical CSF Aβ1-42/Aβ1-40 ratio measurements across two independent laboratories. The high correlation and 100% categorical agreement support the platform’s robust performance and analytical reliability. [Photo] Fred Kim, Head of AriBio U.S., stated, “As we approach the announcement of top-line results from our global Phase 3 trial in 2026, there is growing interest from the scientific and academic communities on the scientific foundation and clinical efficacy of AR1001,” adding, “Our published research, both from internal studies and external collaborations, will serve as a strong foundation to highlight the competitive advantages for AR1001 for future exclusive licensing deals with major pharmaceutical companies and during the commercialization process.” Meanwhile, on the 28th of July, AR1001 was exclusively licensed to Fosun Pharma for the Greater China region through a deal executed by Neuco United. AriBio also plans to enter into an exclusive manufacturing deal with Fosun to supply AR1001 to the Greater China region. The company is also in the process of merging with KOSDAQ-listed Solux, with the merger expected to be finalized in November. [Photo] (From right) James Rock, Chief Clinical Officer of AriBio U.S., and Tanya Xi, Senior Director of Development Strategy, at the 2025 AAIC conference. About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer’s disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. AriBio plans to expand its partnership with Neuco for the Asian territories for the development of future pipeline for neurodegenerative diseases. AR1001, a highly potent and selective second generation PDE5 inhibitor, is a Phase 3, small molecule, oral, disease-modifying therapy for Alzheimer's disease (AD), developed by AriBio Co., Ltd.

The release as fetched from its publisher. aribiogroup.com ↗